Abstract:Background: Type-2 diabetes (T2D) is associated with both reduced and preserved ejection fraction heart failure. Obese db/db mice and Goto Kakizaki (GK) rats represents animals models of T2D that develop cardiac dysfunction similar to human diabetic cardiomyopathy, in which dominant early findings are of diastolic (and not systolic) dysfunction. Circulating extracellular vesicles (EV) contain microRNAs (miR) that can be transferred to recipient cells to modulate their function. We explored whether analysis of EV content from animals models of T2D would inform on the pathophysiology, diagnosis and therapeutic targets of cardiac dysfunction. Hypothesis: EV from animal models of T2D will have altered miR content that contributes to the pathophysiology of diabetic cardiomyopathy. Methods & Results: miR qPCR arrays on circulating EV isolated from plasma of db/db mice reveal several miR (-7, -15, -25, -30e, -148a, -150, -195) modulated during disease progression. These changes in miR content occur prior to echocardiographic evidence of diastolic dysfunction, including global longitudinal strain and strain rate. Among circulating EV miR from the GK rat model, miR-30 was also upregulated (1.42 fold, p=0.03) compared to Wistar rat. In GK rat left ventricle, and in H9C2 rat cardiac myoblast cultured in 25 mM high glucose media, mass spectrometry revealed proteins that were overexpressed in the diabetic heart including oxidative phosphorylation, glycolysis, fatty acid degredation and the citrate cycle. Using a bioinformatics approach, we next identified metabolic pathways affected by miR-30. Based on these findings, in vivo therapy with antagomiR and mimics of miR-30 are underway to test causality and reversibility of the observed cardiomyopathy. Conclusion: EV from animal models of T2D have altered miR content, including miR-30. We also identify alterations in the expression of a network of metabolism genes in the heart, which are implicated in diabetic cardiomyopathy. If causality is supported by experiments that enhance or block miR-30 expression in these models of disease, we will have identified a novel biomarker and therapeutic target for diabetic cardiomyopathy.

Abstract 13380: Administration of Insulin-Like Growth Factor Prevents Cardiac Dysfunction and Expression of Microrna-1 in Apolipoprotein-E Null Mice with Streptozotocin -Induced Diabetes

Administration Of Insulin-Like Growth Factor Prevents Cardiac Dysfunction And Expression Of Microrna-1 In Apolipoprotein-E Null Mice With Streptozotocin -Induced Diabetes

Cardiac Hypertrophy and Dysfunction Induced by Overexpression of Mir-214 in Vivo

MicroRNA Expression Profiles in a Human Induced Pluripotent Stem Cell‐derived Model of Diabetic Cardiomyopathy

Expression profiles and bioinformatic analysis of microRNAs in myocardium of diabetic cardiomyopathy mice

[Mir-494-3p Reduces Insulin Sensitivity in Diabetic Cardiomyocytes by Down-Regulation of Insulin Receptor Substrate 1].

Abstract 16753: Adiponectin Regulates Microrna449b/nfe2l1 Endogenous Antioxidative Pathway, to Ameliorate Cardiac Ischemia Reperfusion Injury in Diabetic Mice

MicroRNAs Involved in the Mitogen-Activated Protein Kinase Cascades Pathway During Glucose-Induced Cardiomyocyte Hypertrophy

Analysis of Microrna Expression Profile in Cardiac Muscle Tissues of Diabetic Mice

Abstract 18021: Overexpression of Microrna-221 Cause Heart Failure by Inhibiting Autophagy

Differentially Expressed Micrornas and Their Target Genes in the Hearts of Streptozotocin-Induced Diabetic Mice

Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice

Upregulated Expression of Mir-1/Mir-206 in a Rat Model of Myocardial Infarction.

Abstract 17406: Inhibition of MicroRNA-133a Expression is Associated with Poor Growth Response of Vascular Smooth Muscle Cells to Insulin-Like Growth Factor-1 in Apolipoprotein-E Deficient Mice

miR-340-5p Mediates Cardiomyocyte Oxidative Stress in Diabetes-Induced Cardiac Dysfunction by Targeting Mcl-1

Compromised diabetic heart function is not affected by miR-378a upregulation upon hyperglycemia

MicroRNA-1 in Cardiac Diseases and Cancers.

In Vivo Inhibition of miR-34a Modestly Limits Cardiac Enlargement and Fibrosis in a Mouse Model with Established Type 1 Diabetes-Induced Cardiomyopathy, but Does Not Improve Diastolic Function

MicroRNA-133a regulates insulin-like growth factor-1 receptor expression and vascular smooth muscle cell proliferation in murine atherosclerosis

Subcellular microRNAs in diabetic cardiomyopathy

Abstract 21261: Circulating Extracellular Vesicles From Mouse and Rat Models of Diabetes Reveal Specific Microrna Signatures as Biomarkers of Diabetic Cardiomyopathy